Anjlee Mahajan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anjlee Mahajan has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Ann Brunson
Center for Oncology Hematology Outcomes Research and Training, Division of Hematology and Oncology University of California Davis Comprehensive Cancer Center Sacramento California USA
5 shared publications Ted Wun
Center for Oncology Hematology Outcomes Research and Training, Division of Hematology Oncology University of California Davis School of Medicine Sacramento California USA
5 shared publicationsAnn Brunson
Division of Hematology and Oncology, Center for Oncology Hematology Outcomes Research and Training , University of California Davis School of Medicine, Sacramento, California, United States
3 shared publications- Ted Wun
University of California-Davis Cancer Center, Sacramento, California, United States
3 shared publications Theresa H. M. Keegan
Center for Oncology Hematology Outcomes Research and Training, Division of Hematology Oncology University of California Davis School of Medicine Sacramento California USA
3 shared publications- Theresa H. M. Keegan
Comprehensive Cancer Center, University of California Davis, Sacramento, USA
3 shared publications
Latest Publications
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (2) , 225-234
Peripheral Neuropathy Incidence in Children, and Adolescents and Young Adults With Cancer and Medicaid Insurance in California
PURPOSE: Chemotherapy-induced peripheral neuropathy is a potentially debilitating adverse effect of cancer therapy that can lead to delay, reduction, or discontinuation of cancer treatment. Population-based data on peripheral neuropathy incidence among young cancer survivors are lacking. METHODS: Using a linkage between Medicaid, the California Cancer Registry, and hospitalization and emergency department data, we identified 6,028 adolescents and young adults (15-39 years) with Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), breast cancer, colorectal cancer, or testicular cancer and 418 children (v 6.2%) and paclitaxel for breast cancer (22.6% v 5.1%). In multivariable analysis, the agents most strongly associated with peripheral neuropathy were brentuximab (±other neurotoxic drugs) for HL (hazard ratio [HR], 9.53 [95% CI, 5.95 to 15.26]); brentuximab (±vinca alkaloids; HR, 7.00 [95% CI, 4.13 to 11.87]) for NHL, paclitaxel for breast cancer (HR, 4.03 [95% CI, 3.05 to 5.31]); oxaliplatin for colorectal cancer (HR, 3.46 [95% CI, 2.23 to 5.36]); and cisplatin and etoposide for testicular cancer (HR, 2.06 [95% CI, 1.37 to 3.11]). CONCLUSION: The high incidence of peripheral neuropathy highlights the need for frequent monitoring, new supportive care approaches, and development of novel therapeutic agents to minimize toxicity while maintaining treatment efficacy.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (2) , 225-234
Peripheral Neuropathy Incidence in Children, and Adolescents and Young Adults With Cancer and Medicaid Insurance in California
PURPOSE: Chemotherapy-induced peripheral neuropathy is a potentially debilitating adverse effect of cancer therapy that can lead to delay, reduction, or discontinuation of cancer treatment. Population-based data on peripheral neuropathy incidence among young cancer survivors are lacking. METHODS: Using a linkage between Medicaid, the California Cancer Registry, and hospitalization and emergency department data, we identified 6,028 adolescents and young adults (15-39 years) with Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), breast cancer, colorectal cancer, or testicular cancer and 418 children (v 6.2%) and paclitaxel for breast cancer (22.6% v 5.1%). In multivariable analysis, the agents most strongly associated with peripheral neuropathy were brentuximab (±other neurotoxic drugs) for HL (hazard ratio [HR], 9.53 [95% CI, 5.95 to 15.26]); brentuximab (±vinca alkaloids; HR, 7.00 [95% CI, 4.13 to 11.87]) for NHL, paclitaxel for breast cancer (HR, 4.03 [95% CI, 3.05 to 5.31]); oxaliplatin for colorectal cancer (HR, 3.46 [95% CI, 2.23 to 5.36]); and cisplatin and etoposide for testicular cancer (HR, 2.06 [95% CI, 1.37 to 3.11]). CONCLUSION: The high incidence of peripheral neuropathy highlights the need for frequent monitoring, new supportive care approaches, and development of novel therapeutic agents to minimize toxicity while maintaining treatment efficacy.
- Open Access
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2)
Cancer-Associated Thrombosis: Surveying Patients' Awareness and Education Needs
PURPOSE: Cancer-associated thrombosis (CAT) is a significant cause of morbidity and mortality. Significant gaps exist in adherence to guidelines suggesting the use of primary thromboprophylaxis in high-risk patients with cancer. Our goal was to understand gaps in patients' awareness of CAT and thromboprophylaxis to better inform future outreach efforts within the framework of shared decision making between patients and providers. PATIENTS AND METHODS: A bilingual (in English and Spanish) questionnaire was designed for individuals with a history of cancer or active cancer by a multidisciplinary expert group including patient advocates, pilot tested and electronically circulated through nonprofit patient advocacy groups for thrombosis and cancer in the United States. Survey domains included (1) risk factor awareness, (2) clinical presentation/diagnosis, (3) treatment, and (4) prevention. We received responses from 140 patients, 41% of whom were actively receiving cancer treatment. RESULTS: Patients demonstrated significant knowledge gaps with regard to CAT, with 61% of patients being unaware of the higher risk of thrombosis in cancer. Patients were open to receiving more information about CAT, including 80% who would like to receive more information from their clinician. A total of 71% of patients would consider the use of thromboprophylaxis if discussed with their provider; however, patients endorsed several concerns about its use including bleeding risk, polypharmacy, and medication interactions. CONCLUSION: Our study demonstrated that there remain significant knowledge gaps regarding CAT and thromboprophylaxis in American patients with cancer. Clinicians remain a trusted source of information about clotting, and a majority of patients are willing to consider thromboprophylaxis if discussed with their provider. Patient education will be an important aspect of increasing adherence to thromboprophylaxis guidelines in high-risk patients with cancer.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 2 (2)
Open AccessCancer-Associated Thrombosis: Surveying Patients' Awareness and Education Needs
PURPOSE: Cancer-associated thrombosis (CAT) is a significant cause of morbidity and mortality. Significant gaps exist in adherence to guidelines suggesting the use of primary thromboprophylaxis in high-risk patients with cancer. Our goal was to understand gaps in patients' awareness of CAT and thromboprophylaxis to better inform future outreach efforts within the framework of shared decision making between patients and providers. PATIENTS AND METHODS: A bilingual (in English and Spanish) questionnaire was designed for individuals with a history of cancer or active cancer by a multidisciplinary expert group including patient advocates, pilot tested and electronically circulated through nonprofit patient advocacy groups for thrombosis and cancer in the United States. Survey domains included (1) risk factor awareness, (2) clinical presentation/diagnosis, (3) treatment, and (4) prevention. We received responses from 140 patients, 41% of whom were actively receiving cancer treatment. RESULTS: Patients demonstrated significant knowledge gaps with regard to CAT, with 61% of patients being unaware of the higher risk of thrombosis in cancer. Patients were open to receiving more information about CAT, including 80% who would like to receive more information from their clinician. A total of 71% of patients would consider the use of thromboprophylaxis if discussed with their provider; however, patients endorsed several concerns about its use including bleeding risk, polypharmacy, and medication interactions. CONCLUSION: Our study demonstrated that there remain significant knowledge gaps regarding CAT and thromboprophylaxis in American patients with cancer. Clinicians remain a trusted source of information about clotting, and a majority of patients are willing to consider thromboprophylaxis if discussed with their provider. Patient education will be an important aspect of increasing adherence to thromboprophylaxis guidelines in high-risk patients with cancer.
- Open Access
- 21 May 2024
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 1 (2)
Association of IVCF use with mortality and intracranial hemorrhage in patients with selected cancers and brain metastasis
- 21 May 2024
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 1 (2)
Open AccessAssociation of IVCF use with mortality and intracranial hemorrhage in patients with selected cancers and brain metastasis
- 8 July 2023
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 56 (3) , 439-446
Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies
Background Direct oral anticoagulant (DOAC) use in cancer-associated venous thromboembolism (CA-VTE) has increased due to updates in recent guidelines and literature. However, select guidelines caution against DOAC use in patients with gastrointestinal (GI) malignancies due to reported increased bleeding events. The objective of this study was to compare the safety and effectiveness of DOACs versus low-molecular-weight heparins (LMWHs) for CA-VTE treatment in patients with GI malignancies. Patients and methods This multicenter, retrospective cohort study included patients with primary GI malignancies who received therapeutic anticoagulation with a DOAC or LMWH for CA-VTE between January 1, 2018, and December 31, 2019. The primary outcome was the incidence rate of bleeding events (major, clinically relevant non-major, or minor bleeding events) within a 12-month period following the initiation of therapeutic anticoagulation. The secondary endpoint was the incidence rate of recurrent VTE events within a 12-month period following the start of therapeutic anticoagulation. Results After screening, 141 patients met inclusion criteria. The incidence rate of all bleeding events significantly differed between DOAC (4.98 events/100 person-months) and LWMH (10.2 events/100 person-months) recipients. The corresponding incidence rate ratio (IRR) with the DOAC group serving as the reference was 2.05 (p = 0.01), with the majority of bleeds in both groups presenting as minor bleeds. No difference was found between the incidence rate of recurrent VTE within a 12-month period of starting therapeutic anticoagulation between groups (IRR 3.08, p = 0.06). Conclusion Our results suggest that DOACs do not pose an additional bleeding risk compared to LMWH in patients with certain GI malignancies. Careful selection of DOAC therapy with respect to bleeding risk is still warranted.
- 8 July 2023
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 56 (3) , 439-446
Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies
Background Direct oral anticoagulant (DOAC) use in cancer-associated venous thromboembolism (CA-VTE) has increased due to updates in recent guidelines and literature. However, select guidelines caution against DOAC use in patients with gastrointestinal (GI) malignancies due to reported increased bleeding events. The objective of this study was to compare the safety and effectiveness of DOACs versus low-molecular-weight heparins (LMWHs) for CA-VTE treatment in patients with GI malignancies. Patients and methods This multicenter, retrospective cohort study included patients with primary GI malignancies who received therapeutic anticoagulation with a DOAC or LMWH for CA-VTE between January 1, 2018, and December 31, 2019. The primary outcome was the incidence rate of bleeding events (major, clinically relevant non-major, or minor bleeding events) within a 12-month period following the initiation of therapeutic anticoagulation. The secondary endpoint was the incidence rate of recurrent VTE events within a 12-month period following the start of therapeutic anticoagulation. Results After screening, 141 patients met inclusion criteria. The incidence rate of all bleeding events significantly differed between DOAC (4.98 events/100 person-months) and LWMH (10.2 events/100 person-months) recipients. The corresponding incidence rate ratio (IRR) with the DOAC group serving as the reference was 2.05 (p = 0.01), with the majority of bleeds in both groups presenting as minor bleeds. No difference was found between the incidence rate of recurrent VTE within a 12-month period of starting therapeutic anticoagulation between groups (IRR 3.08, p = 0.06). Conclusion Our results suggest that DOACs do not pose an additional bleeding risk compared to LMWH in patients with certain GI malignancies. Careful selection of DOAC therapy with respect to bleeding risk is still warranted.
- Open Access
- 4 January 2023
- Published by Wiley in American Journal of Hematology
- Vol. 98 (3) , 440-448
Pregnancy outcomes in women with sickle cell disease in California
Adverse pregnancy outcomes occur frequently in women with sickle cell disease (SCD) across the globe. In the United States, Black women experience disproportionately worse maternal health outcomes than all other racial groups. To better understand how social determinants of health impact SCD maternal morbidity, we used California's Department of Health Care Access and Information data (1991–2019) to estimate the cumulative incidence of pregnancy outcomes in Black women with and without SCD—adjusted for age, insurance status, and Distressed Community Index (DCI) scores. Black pregnant women with SCD were more likely to deliver at a younger age, use government insurance, and live in at‐risk or distressed neighborhoods, compared to those without SCD. They also experienced higher stillbirths (26.8, 95% confidence interval [CI]: 17.5–36.1 vs. 12.4 [CI: 12.1–12.7], per 1000 births) and inpatient maternal mortality (344.5 [CI: 337.6–682.2] vs. 6.1 [CI: 2.3–8.4], per 100 000 live births). Multivariate logistic regression models showed Black pregnant women with SCD had significantly higher odds ratios (OR) for sepsis (OR 14.89, CI: 10.81, 20.52), venous thromboembolism (OR 13.60, CI: 9.16, 20.20), and postpartum hemorrhage (OR 2.25, CI 1.79–2.82), with peak onset in the second trimester, third trimester, and six weeks postpartum, respectively. Despite adjusting for sociodemographic factors, Black women with SCD still experienced significantly worse pregnancy outcomes than those without SCD. We need additional studies to determine if early introduction to reproductive health education, continuation of SCD‐modifying therapies during pregnancy, and increasing access to multidisciplinary perinatal care can reduce morbidity in pregnant women with SCD.
- 4 January 2023
- Published by Wiley in American Journal of Hematology
- Vol. 98 (3) , 440-448
Open AccessPregnancy outcomes in women with sickle cell disease in California
Adverse pregnancy outcomes occur frequently in women with sickle cell disease (SCD) across the globe. In the United States, Black women experience disproportionately worse maternal health outcomes than all other racial groups. To better understand how social determinants of health impact SCD maternal morbidity, we used California's Department of Health Care Access and Information data (1991–2019) to estimate the cumulative incidence of pregnancy outcomes in Black women with and without SCD—adjusted for age, insurance status, and Distressed Community Index (DCI) scores. Black pregnant women with SCD were more likely to deliver at a younger age, use government insurance, and live in at‐risk or distressed neighborhoods, compared to those without SCD. They also experienced higher stillbirths (26.8, 95% confidence interval [CI]: 17.5–36.1 vs. 12.4 [CI: 12.1–12.7], per 1000 births) and inpatient maternal mortality (344.5 [CI: 337.6–682.2] vs. 6.1 [CI: 2.3–8.4], per 100 000 live births). Multivariate logistic regression models showed Black pregnant women with SCD had significantly higher odds ratios (OR) for sepsis (OR 14.89, CI: 10.81, 20.52), venous thromboembolism (OR 13.60, CI: 9.16, 20.20), and postpartum hemorrhage (OR 2.25, CI 1.79–2.82), with peak onset in the second trimester, third trimester, and six weeks postpartum, respectively. Despite adjusting for sociodemographic factors, Black women with SCD still experienced significantly worse pregnancy outcomes than those without SCD. We need additional studies to determine if early introduction to reproductive health education, continuation of SCD‐modifying therapies during pregnancy, and increasing access to multidisciplinary perinatal care can reduce morbidity in pregnant women with SCD.
- 17 January 2022
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 122 (08) , 1407-1414
Incidence and Outcomes Associated with 6,841 Isolated Distal Deep Vein Thromboses in Patients with 13 Common Cancers
Introduction The epidemiology of isolated distal deep venous thrombosis (iDDVT) among cancer patients is not well described, particularly the incidence of recurrent venous thromboembolism (rVTE) and effect on mortality by cancer type. Methods The cumulative incidence (CI) of iDDVT was determined for patients with 13 common cancers between 2005 and 2017 using the California Cancer Registry linked to the California Patient Discharge and Emergency Department Utilization datasets. The CI of rVTE was calculated and association of incident cancer-associated thrombosis (CT) location with rVTE was determined using Cox proportional hazards regression models. The association of incident CT location with overall and cancer-specific mortality was determined using Cox models, stratified by cancer site, and adjusted for individual characteristics. Results Among 942,109 cancer patients, CT occurred in 62,003 (6.6%): of these, 6,841 (11.0%) were iDDVT. Compared with more proximal sites of CT, iDDVT was associated with similar risk for rVTE. IDDVT was associated with increased mortality across all cancer types when compared with patients without CT (hazard ratio: 1.56–4.60). The effect of iDDVT on mortality was similar to that of proximal DVT (pDVT) for most cancers except lung, colorectal, bladder, uterine, brain, and myeloma, where iDDVT was associated with a lesser association with mortality. Conclusion iDDVT represented 11% of CT. The risk of rVTE after iDDVT was similar to other sites of CT and rVTE occurred in more proximal locations after an incident iDDVT. IDDVT was associated with increased mortality and this effect was similar to that of pulmonary embolism or pDVT for most cancer types.
- 17 January 2022
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 122 (08) , 1407-1414
Incidence and Outcomes Associated with 6,841 Isolated Distal Deep Vein Thromboses in Patients with 13 Common Cancers
Introduction The epidemiology of isolated distal deep venous thrombosis (iDDVT) among cancer patients is not well described, particularly the incidence of recurrent venous thromboembolism (rVTE) and effect on mortality by cancer type. Methods The cumulative incidence (CI) of iDDVT was determined for patients with 13 common cancers between 2005 and 2017 using the California Cancer Registry linked to the California Patient Discharge and Emergency Department Utilization datasets. The CI of rVTE was calculated and association of incident cancer-associated thrombosis (CT) location with rVTE was determined using Cox proportional hazards regression models. The association of incident CT location with overall and cancer-specific mortality was determined using Cox models, stratified by cancer site, and adjusted for individual characteristics. Results Among 942,109 cancer patients, CT occurred in 62,003 (6.6%): of these, 6,841 (11.0%) were iDDVT. Compared with more proximal sites of CT, iDDVT was associated with similar risk for rVTE. IDDVT was associated with increased mortality across all cancer types when compared with patients without CT (hazard ratio: 1.56–4.60). The effect of iDDVT on mortality was similar to that of proximal DVT (pDVT) for most cancers except lung, colorectal, bladder, uterine, brain, and myeloma, where iDDVT was associated with a lesser association with mortality. Conclusion iDDVT represented 11% of CT. The risk of rVTE after iDDVT was similar to other sites of CT and rVTE occurred in more proximal locations after an incident iDDVT. IDDVT was associated with increased mortality and this effect was similar to that of pulmonary embolism or pDVT for most cancer types.
- Top Cited PapersOpen Access
- 11 January 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (1) , 307-320
The incidence of cancer-associated thrombosis is increasing over time
Cancer-associated thrombosis (CAT) is an important cause of morbidity and mortality for patients with malignancy and varies by primary cancer type, stage, and therapy. We aimed to characterize the incidence, risk factors, temporal trends, and the effect on mortality of CAT. The California Cancer Registry was linked to the statewide hospitalization database to identify individuals with the 13 most common malignancies diagnosed between 2005 and 2017 and determine the 6- and 12-month cumulative incidence of CAT by venous thromboembolism (VTE) location, tumor type, and stage after adjusting for competing risk of death. Cox proportional hazard regression models were used to determine risk factors associated with CAT and the effect of CAT on all-cause mortality. 942 019 patients with cancer were identified; 62 003 (6.6%) had an incident diagnosis of CAT. Patients with pancreatic, brain, ovarian, and lung cancer had the highest, and patients with breast and prostate cancer had the lowest 12-month cumulative incidence of CAT. For most malignancies, men, those with metastatic disease and more comorbidities, and African Americans (vs non-Hispanic Whites) were at highest risk for CAT. Patients diagnosed with cancer between 2014 and 2017 had a higher risk of CAT compared with those diagnosed between 2005 and 2007. CAT was associated with increased overall mortality for all malignancies (HR ranges 1.89 to 4.79). The incidence of CAT increased over time and was driven by an increase in pulmonary embolism±deep vein thrombosis (PE±DVT). CAT incidence varies based on tumor type and stage and on individual risk factors including gender, race/ethnicity, and comorbidities. For all tumor types, CAT is associated with an increased mortality.
- 11 January 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (1) , 307-320
Top Cited PapersOpen AccessThe incidence of cancer-associated thrombosis is increasing over time
Cancer-associated thrombosis (CAT) is an important cause of morbidity and mortality for patients with malignancy and varies by primary cancer type, stage, and therapy. We aimed to characterize the incidence, risk factors, temporal trends, and the effect on mortality of CAT. The California Cancer Registry was linked to the statewide hospitalization database to identify individuals with the 13 most common malignancies diagnosed between 2005 and 2017 and determine the 6- and 12-month cumulative incidence of CAT by venous thromboembolism (VTE) location, tumor type, and stage after adjusting for competing risk of death. Cox proportional hazard regression models were used to determine risk factors associated with CAT and the effect of CAT on all-cause mortality. 942 019 patients with cancer were identified; 62 003 (6.6%) had an incident diagnosis of CAT. Patients with pancreatic, brain, ovarian, and lung cancer had the highest, and patients with breast and prostate cancer had the lowest 12-month cumulative incidence of CAT. For most malignancies, men, those with metastatic disease and more comorbidities, and African Americans (vs non-Hispanic Whites) were at highest risk for CAT. Patients diagnosed with cancer between 2014 and 2017 had a higher risk of CAT compared with those diagnosed between 2005 and 2007. CAT was associated with increased overall mortality for all malignancies (HR ranges 1.89 to 4.79). The incidence of CAT increased over time and was driven by an increase in pulmonary embolism±deep vein thrombosis (PE±DVT). CAT incidence varies based on tumor type and stage and on individual risk factors including gender, race/ethnicity, and comorbidities. For all tumor types, CAT is associated with an increased mortality.
- Open Access
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 489
Pregnancy Outcomes in Women with Sickle Cell Disease in California: A Retrospective Cohort Study
Background: Women with sickle cell disease (SCD) are at high risk for obstetrical and SCD-related complications throughout pregnancy. Given the dearth of recent population-based studies on female reproductive health in SCD, we used hospitalization data from the socio-economically diverse state of California to describe peripartum outcomes in women with SCD. Methods: For our retrospective cohort study, we identified females with SCD who were either evaluated in the emergency department (ED) or hospitalized between the ages of 10-45 years from California's patient discharge dataset (1991-2016). We defined SCD severity by frequency of utilization with severe disease requiring an average of ≥ 3 hospitalizations and/or ED visits per year, and less severe with an annual rate of < 3 acute care visits. We used ICD-9/10-CM codes to identify all deliveries, and categorized pregnancy outcomes as either incomplete (hydatidiform mole, elective termination, miscarriage, and ectopic pregnancies) or delivery (live or stillbirths). We defined race/ethnicity as Black (or African American) vs. non-Black and quantified the total number of pregnancies for each patient. We described delivery age, mode (C-section vs. vaginal), outcome (live vs. stillbirth), median length of stay (LOS), and maternal mortality for the first in-hospital delivery. Results: Our cohort comprised 3,089 females with SCD of childbearing age, with a median follow-up of 11 years. Of the 1,108 (35.9%) women with at least one pregnancy, 1,000 (90.3%) were Black and 591 (53.3%) had severe SCD. Overall, we observed 2,330 pregnancies; of the 1,864 (80%) deliveries , 45% occurred via C-section (Figure 1). When we restricted our analysis to first deliveries only, 346 (36.0%) occurred in women ages 20-24 years; the next highest proportion of deliveries (23.4%) was in adolescents ages 15-19 years (Figure 2). Only 5.5% of deliveries occurred in women ≥ 35 years old. One hundred seventy-two (15.5%) first pregnancies were incomplete (Table 1), primarily due to miscarriage (59.3%). Of the women with incomplete first pregnancies, 69.2% had severe SCD; in contrast, 50.4% had severe SCD in the first delivered pregnancies' subset. Of the 936 first deliveries, 41.5% were by C-section with a median LOS of 5 days, compared with 3 days for those who delivered vaginally. Twenty-two first deliveries (2.4%) were stillbirth for a rate of 24.9 stillbirths per 1000 deliveries. Of the 862 live births, 5 women died, which resulted in an inpatient maternal mortality rate of 580.1 per 100,000 live births. Discussion Pregnant women with SCD first delivered in the hospital at a mean age of 24.1 years, which is younger than the US national mean of 26.8 years (all races) and 24.9 years (Black), based on 2017 maternal health data from the Centers for Disease Control and Prevention (CDC). We attribute this age difference to the higher proportion of first deliveries in adolescents with SCD coupled with the trend towards older age of first delivery in the general population. For first deliveries, 41.5% of women with SCD underwent a C-section, compared with a 2013 national average of 22.8% (all races) and 25.7% (Black) in primigravid women in the US. Stillbirths in our SCD cohort surpassed the 2014 national rates of 5.9 (all races) and 10.3 (Black) stillbirths per 1000 deliveries. Lastly, the inpatient maternal mortality rate in women with SCD, while based only on 5 deaths, far exceeds the 2014-2017 US maternal mortality rates of 17.3 (all races) and 41.7 (Black) deaths per 100,000 live births. Limitations include the lack of outpatient data, which likely resulted in an underestimation of the total number of pregnancies. Maternal mortality rates from the CDC cover death up to 12 months postpartum, so a comparable mortality rate for women with SCD might be higher. The striking disparities in outcomes in our study cohort, compared to national averages, suggests notable deficits in the optimal management of pregnancy in SCD. Analyses are ongoing to determine the effect of pregnancy on sickle-cell related complications, to evaluate the frequency of peripartum complications in women with SCD (e.g., venous thromboembolism, preeclampsia, and post-partum hemorrhage), and to compare rates of obstetrical complications in SCD vs non-SCD women, adjusted for social determinants of health. Figure 1 Figure 1. Disclosures: No relevant conflicts of interest to declare.
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 489
Open AccessPregnancy Outcomes in Women with Sickle Cell Disease in California: A Retrospective Cohort Study
Background: Women with sickle cell disease (SCD) are at high risk for obstetrical and SCD-related complications throughout pregnancy. Given the dearth of recent population-based studies on female reproductive health in SCD, we used hospitalization data from the socio-economically diverse state of California to describe peripartum outcomes in women with SCD. Methods: For our retrospective cohort study, we identified females with SCD who were either evaluated in the emergency department (ED) or hospitalized between the ages of 10-45 years from California's patient discharge dataset (1991-2016). We defined SCD severity by frequency of utilization with severe disease requiring an average of ≥ 3 hospitalizations and/or ED visits per year, and less severe with an annual rate of < 3 acute care visits. We used ICD-9/10-CM codes to identify all deliveries, and categorized pregnancy outcomes as either incomplete (hydatidiform mole, elective termination, miscarriage, and ectopic pregnancies) or delivery (live or stillbirths). We defined race/ethnicity as Black (or African American) vs. non-Black and quantified the total number of pregnancies for each patient. We described delivery age, mode (C-section vs. vaginal), outcome (live vs. stillbirth), median length of stay (LOS), and maternal mortality for the first in-hospital delivery. Results: Our cohort comprised 3,089 females with SCD of childbearing age, with a median follow-up of 11 years. Of the 1,108 (35.9%) women with at least one pregnancy, 1,000 (90.3%) were Black and 591 (53.3%) had severe SCD. Overall, we observed 2,330 pregnancies; of the 1,864 (80%) deliveries , 45% occurred via C-section (Figure 1). When we restricted our analysis to first deliveries only, 346 (36.0%) occurred in women ages 20-24 years; the next highest proportion of deliveries (23.4%) was in adolescents ages 15-19 years (Figure 2). Only 5.5% of deliveries occurred in women ≥ 35 years old. One hundred seventy-two (15.5%) first pregnancies were incomplete (Table 1), primarily due to miscarriage (59.3%). Of the women with incomplete first pregnancies, 69.2% had severe SCD; in contrast, 50.4% had severe SCD in the first delivered pregnancies' subset. Of the 936 first deliveries, 41.5% were by C-section with a median LOS of 5 days, compared with 3 days for those who delivered vaginally. Twenty-two first deliveries (2.4%) were stillbirth for a rate of 24.9 stillbirths per 1000 deliveries. Of the 862 live births, 5 women died, which resulted in an inpatient maternal mortality rate of 580.1 per 100,000 live births. Discussion Pregnant women with SCD first delivered in the hospital at a mean age of 24.1 years, which is younger than the US national mean of 26.8 years (all races) and 24.9 years (Black), based on 2017 maternal health data from the Centers for Disease Control and Prevention (CDC). We attribute this age difference to the higher proportion of first deliveries in adolescents with SCD coupled with the trend towards older age of first delivery in the general population. For first deliveries, 41.5% of women with SCD underwent a C-section, compared with a 2013 national average of 22.8% (all races) and 25.7% (Black) in primigravid women in the US. Stillbirths in our SCD cohort surpassed the 2014 national rates of 5.9 (all races) and 10.3 (Black) stillbirths per 1000 deliveries. Lastly, the inpatient maternal mortality rate in women with SCD, while based only on 5 deaths, far exceeds the 2014-2017 US maternal mortality rates of 17.3 (all races) and 41.7 (Black) deaths per 100,000 live births. Limitations include the lack of outpatient data, which likely resulted in an underestimation of the total number of pregnancies. Maternal mortality rates from the CDC cover death up to 12 months postpartum, so a comparable mortality rate for women with SCD might be higher. The striking disparities in outcomes in our study cohort, compared to national averages, suggests notable deficits in the optimal management of pregnancy in SCD. Analyses are ongoing to determine the effect of pregnancy on sickle-cell related complications, to evaluate the frequency of peripartum complications in women with SCD (e.g., venous thromboembolism, preeclampsia, and post-partum hemorrhage), and to compare rates of obstetrical complications in SCD vs non-SCD women, adjusted for social determinants of health. Figure 1 Figure 1. Disclosures: No relevant conflicts of interest to declare.
- 23 June 2020
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (11) , 2605-2613
High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma
Venous thromboembolism (VTE) and major bleeding in primary central nervous system lymphoma (PCNSL) patients are not well described. We identified 992 PCNSL patients using the California Cancer Registry (2005–2014). The cumulative incidence of VTE and major bleeding was determined using California hospitalization data. The 12-month cumulative incidence of VTE was 13.6% (95% confidence interval (CI) 11.5–15.8%); chemotherapy and radiation therapy were associated with increased risk of VTE (hazard ratio (HR) 2.41, CI 1.31–4.46 and HR 1.56, CI 1.08–2.25, respectively). The 12-month cumulative incidence of major bleeding was 12.4% (CI 10.1–14.6%). Pulmonary embolism (PE) and proximal deep vein thrombosis were associated with increased risk of major bleeding, likely due to anticoagulation. PE (HR 1.61, CI 1.11–2.33, p=.011) and major bleeding (HR 2.36, CI 1.82–3.06, p<.0001) were associated with increased mortality. This study highlights the high incidence of both VTE and major bleeding and the significant impact on survival for PCNSL patients.
- 23 June 2020
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (11) , 2605-2613
High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma
Venous thromboembolism (VTE) and major bleeding in primary central nervous system lymphoma (PCNSL) patients are not well described. We identified 992 PCNSL patients using the California Cancer Registry (2005–2014). The cumulative incidence of VTE and major bleeding was determined using California hospitalization data. The 12-month cumulative incidence of VTE was 13.6% (95% confidence interval (CI) 11.5–15.8%); chemotherapy and radiation therapy were associated with increased risk of VTE (hazard ratio (HR) 2.41, CI 1.31–4.46 and HR 1.56, CI 1.08–2.25, respectively). The 12-month cumulative incidence of major bleeding was 12.4% (CI 10.1–14.6%). Pulmonary embolism (PE) and proximal deep vein thrombosis were associated with increased risk of major bleeding, likely due to anticoagulation. PE (HR 1.61, CI 1.11–2.33, p=.011) and major bleeding (HR 2.36, CI 1.82–3.06, p<.0001) were associated with increased mortality. This study highlights the high incidence of both VTE and major bleeding and the significant impact on survival for PCNSL patients.
- 18 July 2019
- Published by Springer Nature
- Vol. 179, 69-85
Biomarkers of Cancer-Associated Thromboembolism
Venous thromboembolism is known to be associated with an increase in morbidity and mortality in patients with malignancy. Predictive laboratory biomarkers of venous thromboembolism (VTE) have long been sought after to improve outcomes and help guide clinical decision making. Previously studied biomarkers include C reactive protein (CRP), tissue factor expressing microparticles (TF MP), D-dimer, soluble P-selectin (sP-selectin), plasminogen activator inhibitor 1 (PAI-1), factor VIII, platelet count, and leukocyte counts. This chapter will focus on these possible biomarkers for cancer-associated thrombosis (CAT) with particular emphasis on the pathophysiology behind thrombosis formation as well as data from clinical studies in patients with malignancy. The incorporation of the above biomarkers into risk assessment tools to predict CAT will also be reviewed, as will risk factors for recurrent VTE in patients with malignancy. Further studies are ongoing to develop readily available biomarkers that can be incorporated into future risk assessment models with the goal of reducing morbidity and mortality due to cancer-associated thrombosis.
- 18 July 2019
- Published by Springer Nature
- Vol. 179, 69-85
Biomarkers of Cancer-Associated Thromboembolism
Venous thromboembolism is known to be associated with an increase in morbidity and mortality in patients with malignancy. Predictive laboratory biomarkers of venous thromboembolism (VTE) have long been sought after to improve outcomes and help guide clinical decision making. Previously studied biomarkers include C reactive protein (CRP), tissue factor expressing microparticles (TF MP), D-dimer, soluble P-selectin (sP-selectin), plasminogen activator inhibitor 1 (PAI-1), factor VIII, platelet count, and leukocyte counts. This chapter will focus on these possible biomarkers for cancer-associated thrombosis (CAT) with particular emphasis on the pathophysiology behind thrombosis formation as well as data from clinical studies in patients with malignancy. The incorporation of the above biomarkers into risk assessment tools to predict CAT will also be reviewed, as will risk factors for recurrent VTE in patients with malignancy. Further studies are ongoing to develop readily available biomarkers that can be incorporated into future risk assessment models with the goal of reducing morbidity and mortality due to cancer-associated thrombosis.